<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28262">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01706016</url>
  </required_header>
  <id_info>
    <org_study_id>2012-A00448-35</org_study_id>
    <secondary_id>2011/1773</secondary_id>
    <nct_id>NCT01706016</nct_id>
  </id_info>
  <brief_title>Local Treatment by Thermic Destruction of Primitive Breast Cancer</brief_title>
  <acronym>LASERBREAST1</acronym>
  <official_title>Local Treatment by Thermic Destruction of Primitive Breast Cancer. Phase II: Feasibility and Effectiveness, Standardization of Procedures.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate the effectiveness of laser in the treatment of cancerous lesions by
      determinating with histological analysis of the specimen the percentage of tumor cells
      remaining in the area treated by the laser
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Effectiveness of laser treatment</measure>
    <time_frame>28 days after initial diagnosis</time_frame>
    <safety_issue>No</safety_issue>
    <description>Destruction of the carcinoma will be assess by histological analysis of the specimen.
If more than 10% of viables cancerous cells are remaining in the volume treated by laser, the procedure would be a fail</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Life quality</measure>
    <time_frame>D-0 and before the surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Life quality will be assess using the questionnaire QLQ-C30 breast module BR23-version 3</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thermic destruction of tissue by Laser using the Novilase device</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Noninflammatory unilateral and unifocal breast cancer

          -  Size &lt;/= 20mm (ultrasound measure)

          -  Histological confirmation of cancer by biopsy grade status hormone and HER2.

          -  Good delineation of the lesion on ultrasound.

          -  Minimum distance of 5 mm between the tumor and the skin between the tumor and muscle.

          -  Age between 18 and 80

          -  ECOG performance status 0 or 1
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Remy GARBAY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean Remy GARBAY, MD</last_name>
    <phone>+33 1 42 11 43 50</phone>
    <email>garbay@igr.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ariane DUNANT</last_name>
    <phone>+33 1 42 11 53 89</phone>
    <email>adunant@igr.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Remy GARBAY, MD</last_name>
      <phone>+33 1 42 11 43 50</phone>
      <email>garbay@igr.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Remy GARBAY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 12, 2012</lastchanged_date>
  <firstreceived_date>October 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
